Healthcare Industry News: MaxPlus
News Release - March 10, 2008
Medegen Introduces MaxPlus(R) Clear, First and Only Clear Positive Displacement Connector for Use in Infusion TherapyShown to Enhance Patient Care Leading to Lower Bloodstream Infection and Occlusion Rates
ONTARIO, Calif.--(HSMN NewsFeed)--Maximus, a business unit of leading infusion therapy firm Medegen Inc., today introduced its MaxPlus® Clear positive displacement connector for use in patient care. MaxPlus Clear provides complete visualization of the fluid path providing a visual reminder to completely perform clinical practices such as priming, disinfection, and flushing. This clarity enhances clinical practice which can ultimately reduce the occurrence of bloodstream infections and occlusions in patients receiving infusion therapy.
Maximus is the only medical device manufacturer to offer a clear positive displacement connector.
"MaxPlus Clear was developed based on the input from leading clinical institutions and practitioners. The MaxPlus' positive displacement feature, combined with a clear housing, offers complete visualization of the fluid path thereby enhancing catheter care," said Jeffrey Goble, President of Medegen. "Our goal is to significantly assist clinicians in their efforts to promote patient safety by providing them with products that assure clinical best practices will be effective, resulting in lower occurrences of catheter-related blood stream infection and occlusions."
The MaxPlus Clear is an enhancement of the MaxPlus®, the company’s leading positive displacement connector, adding a clear housing. It features Medegen’s patented positive displacement technology, which provides a bolus of fluid to clear the catheter tip upon disconnection from the device. It also features Medegen’s patented Tru-Swab™ top which acts as a double sealed barrier to contamination and allows for true disinfection during pre-access swabbing.
Medegen’s MaxPlus Clear provides features not previously available to clinicians, and is new technology for the industry.
MaxPlus Clear answers the need of medical practitioners in a number of ways:
- Provides for complete visualization of the fluid path during priming and flushing of the device
- Promotes an “Occlusion, and Contaminant Free” Line
- Promotes compliance with best practices and aseptic technique
- Promotes the use of Saline Flush and Lock vs. Heparin
- Promotes complete flushing
- Bloodstream infections
- Heparin usage
- False positive blood cultures
- Nursing time
- And all the costs associated with the above
MaxPlus Clear is available in the U.S. beginning immediately. MaxPlus Clear will be sold and distributed through Maximus. For sales and product inquiries, contact 909-390-9080 or www.maximusmedical.com.
About Medegen Inc.
Medegen is a leading innovator in infusion therapy, focused on helping hospitals drive greater clinical performance for improved patient care. The growing company provides clinically superior medical products and reliable, cost-effective manufacturing services to the medical community through its three operating units: Manufacturing Services, Maximus and KippMed. Manufacturing Services provides cost-effective contract manufacturing solutions to medical device, drug delivery and pharmaceutical companies. KippMed manufactures and markets IV therapy components for the OEM market, drawing from a 25-year history in IV component supply. Maximus develops, manufactures and markets needleless intravenous therapy products for the acute care market. The Maximus line of medical products feature patent-protected technologies which improve patient outcomes and greatly reduce bloodstream infection rates. Medegen is headquartered in Ontario, Calif., with executive offices in Scottsdale, Ariz., and operations in Tijuana, Mexico. For more, visit http://www.medegen.com/.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.